This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-21 and is reviewed periodically as new material appears.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
== Early life and education == Wittliff was born on June 15, 1938 in Taft, Texas, of primarily Eastern European heritage. He is a 6th generation Texan and direct descendant of John Cryer (Crier), who was recruited to settle Texas as part of Stephen F. Austin's original 300 families. He, his brother Bill and their mother Laura moved to Blanco when they were boys. In 1956, Wittliff graduated from San Marcos Academy, a college preparatory school that emphasized military discipline and training at the time. After 2 years of studying Chemical Engineering at Texas Tech University where he was a writer for The Daily Toreador and the National Publication Headquarters for the Arnold Air Society, he received a bachelor's degree in chemistry from University of Texas at Austin. While at UT, Wittliff worked at Clyde Campbell University Shop and modeled to support his education. Wittliff then earned an M. S. Degree in Biochemistry at Louisiana State University, School of Medicine. Wittliff's family moved to the University of Texas at Austin where he was awarded an National Defense Education Act (NDEA) Fellowship, a program influenced by the launch of the Sputnik satellite by the Soviets. Wittliff received his Ph.D. degree at The University of Texas at Austin in 1967. He then received an NIH Postdoctoral Award to study in the Laboratory of Professor Francis T. Kenney in the Biology Division at Oak Ridge National Laboratory.
=== Thomson Medal Award (since 1985) === 2024 Jennifer S. Brodbelt 2022 Vicki Wysocki and Lidia Gall 2020 Alison E. Ashcroft 2014 Carol V. Robinson 2009 Catherine E. Costello and Catherine. C. Fenselau
==== General Conference ==== The General Conference of the IIR defines the general policy of the IIR and convenes once every four years during its international congress. It includes representatives appointed by member countries. The General Conference elects the president and vice presidents of the executive committee.
On 20 October 2001, an element of ODA 595 guided in the first JDAM bomb from a B-52, impressing General Dostum and his Northern Alliance forces who soon used it for Psychological warfare – taunted the Taliban over their radio frequencies. On 9 November 2001, ODA 595 and ODA 534 and the seven members of the CIA's Special Activities Division assisted about 2000 members of the Northern Alliance who attacked and liberated Mazari Sharif on horseback, foot, pickup trucks, and BMP armored personnel carriers. On November 11, in the central north of Afghanistan, ODA 586 was advising General Daoud Khan outside the city of Taloqan and coordinating a batch of preparatory airstrikes when the General surprised everyone by launching an impromptu massed infantry assault on the Taliban holding the city. Before the first bomb could be dropped, the city fell. On 12 and 13 November, ODA 555 assisted the Northern Alliance forces in the capture of Kabul. On November 14, 2001, ODA 574 and Hamid Karzai inserted into Uruzgan Province via 4 MH-60K helicopters and later fought the Battle of Tarwinkot with a small force of guerrillas. On 23 November, ODA 586 assisted General Daoud Khan forces in the taking Kunduz. On 25 November, a headquarters element from 3rd Battalion, 5th SFG, along with British SBS and other US forces took part in the Battle of Qala-i-Jangi, on 27 November, during a CAS mission, 5 Green Berets were wounded by a misdirected JDAM. Various ODA's took part in the taking of Kandahar.
88H Cargo Specialist 88K Watercraft Operator 88L Watercraft Engineer 88M Motor Transport Operator 88N Transportation Management Coordinator 88P Railway Equipment Repairer (RC) 88T Railway Section Repairer (RC) 88U Railway Operations Crew Member (RC) 88Z Transportation Senior Sergeant
Sources: en.wikipedia.org
== Pharmacodynamic properties == Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract, thus decreasing the constipating effects (slowing of gastrointestinal motility and transit, hypertonicity, increased fluid reabsorption) associated with opioids. If naloxegol is coadministered with other opioid antagonists, there is a potential for additive effect and increased risk of opioid withdrawal.
In 2024, McGregor and Boorman – with their principal support crew from the previous Long Way journeys – undertook a fourth international trip, this time on a 1974 Moto Guzzi Eldorado police motorcycle, while Boorman chose a BMW R75/5. This was documented in the 2025 series Long Way Home.
The two amphetamine enantiomers that compose Adderall, such as Adderall tablets/capsules (levoamphetamine and dextroamphetamine), alleviate the symptoms of ADHD and narcolepsy by increasing the activity of the neurotransmitters norepinephrine and dopamine in the brain, which results in part from their interactions with human trace amine-associated receptor 1 (hTAAR1) and vesicular monoamine transporter 2 (VMAT2) in neurons. Dextroamphetamine is a more potent CNS stimulant than levoamphetamine, but levoamphetamine has slightly stronger cardiovascular and peripheral effects and a longer elimination half-life than dextroamphetamine. The active ingredient in Adderall, amphetamine, shares many chemical and pharmacological properties with the human trace amines, particularly phenethylamine and N-methylphenethylamine, the latter of which is a positional isomer of amphetamine. In 2023, Adderall was the fifteenth most commonly prescribed medication in the United States, with more than 32 million prescriptions.
The shark population has benefited significantly from the surge in seal numbers following the Marine Mammal Protection Act in 1972, and as many as 800 individual white sharks are documented visiting the Cape Cod area.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.